Drug ID:Drug198
Drug Name:Bictegravir
CID:90311989
DrugBank ID:DB11799
Modality:Small Molecule
Groups:NULL
US Approved:YES
Other Approved:YES
Identifier: NCT04518228, , NCT05502341, , NCT06333808, , NCT06629480, , NCT05979311, , NCT04805944, , NCT03711253, , NCT03499483, , NCT02275065, , NCT02400307
Molecular Formula:C21H18F3N3O5
Molecular Weight:449.4 g/mol
Isomeric SMILES:C1C[C@@H]2C[C@H]1N3[C@H](O2)CN4C=C(C(=O)C(=C4C3=O)O)C(=O)NCC5=C(C=C(C=C5F)F)F
Synonyms:Bictegravir; 1611493-60-7; GS-9883; Bictegravir [INN]; GS-9883-01; bictegravirum; Bictegravir [USAN:INN]; (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide; 8GB79LOJ07; BICTEGRAVIR [MI]
Phase 0: 0
Phase 1: 13
Phase 2: 19
Phase 3: 33
Phase 4: 41
Description:NULL

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
dt1393 90311989 Bictegravir 1576 CYP3A4 Homo sapiens (human) Substrate
dt1394 90311989 Bictegravir 54658 UGT1A1 Homo sapiens (human) Substrate
dt1395 90311989 Bictegravir 5452 POU2F2 Homo sapiens (human) Inhibitor
dt1396 90311989 Bictegravir 55244 SLC47A1 Homo sapiens (human) Inhibitor
dt1397 90311989 Bictegravir None -- Severe acute respiratory syndrome coronavirus 2 34798775 None
dt1398 90311989 Bictegravir None -- Human immunodeficiency virus 1 Human immunodeficiency virus type 1 integrase inhibitor
dt1399 90311989 Bictegravir 8854 ALDH1A2 Mus musculus (house mouse) 34515794 Bictegravir results in decreased expression of ALDH1A2 mRNA
dt1400 90311989 Bictegravir 1592 CYP26A1 Mus musculus (house mouse) 34515794 Bictegravir results in increased expression of CYP26A1 mRNA
dt1401 90311989 Bictegravir 83881 MIXL1 Mus musculus (house mouse) 34515794 Bictegravir results in increased expression of MIXL1 mRNA
dt1402 90311989 Bictegravir 2253 FGF8 Mus musculus (house mouse) 34515794 Bictegravir results in increased expression of FGF8 mRNA

  • No data available

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
NCT05687474 Baby Detect : Genomic Newborn Screening NULL COMPLETED Centre Hospitalier Universitaire de Liege Congenital Adrenal Hyperplasia|Familial Hyperinsu… None Details
NCT05668013 A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease PHASE2 ACTIVE_NOT_RECRUITING Teva Branded Pharmaceutical Products R&D LLC Crohn Disease|Colitis, Ulcerative DRUG: TEV-48574 Dose Regimen A|DRUG: TEV-48574 Do… Details
NCT07168434 Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome PHASE3 RECRUITING Biocodex IBS (Irritable Bowel Syndrome)|IBS-D (Diarrhea-pr… DRUG: Saccharomyces Boulardii 250 MG|DRUG: Placeb… Details
NCT05588843 Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis PHASE2 ACTIVE_NOT_RECRUITING Sanofi Colitis Ulcerative DRUG: SAR443122|DRUG: Placebo Details
NCT05575505 Phosphodiesterase Inhibitors, Pentoxifylline, as Adjunctive Therapy in Patients With Ulcerative Colitis. PHASE2 RECRUITING Tanta University Inflammatory Bowel Diseases DRUG: Pentoxifylline 400 MG Details
NCT05558761 Pentoxifylline as Adjunctive Therapy in Patients With Ulcerative Colitis PHASE2 COMPLETED Tanta University Inflammatory Bowel Diseases DRUG: Pentoxifylline 400 MG Details
NCT05549323 A Study to Learn About the Safety, Effects and Pharmacokinetics of Study Medication (PF-07054894) for the Treatment of Ulcerative Colitis PHASE1 TERMINATED Pfizer Ulcerative Colitis DRUG: PF-07054894|DRUG: Placebo Details
NCT05535946 ABTECT - Maintenance PHASE3 ACTIVE_NOT_RECRUITING Abivax S.A. Ulcerative Colitis DRUG: ABX464|DRUG: Placebo Details
NCT05509777 A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease PHASE3 RECRUITING Eli Lilly and Company Crohn's Disease DRUG: Mirikizumab Details
NCT05507216 ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 PHASE3 COMPLETED Abivax S.A. Ulcerative Colitis DRUG: ABX464|DRUG: Placebo Details
NCT05507203 ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 PHASE3 COMPLETED Abivax S.A. Ulcerative Colitis DRUG: ABX464|DRUG: Placebo Details
NCT05499130 A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease PHASE2 COMPLETED Teva Branded Pharmaceutical Products R&D, Inc. Crohn Disease|Colitis, Ulcerative DRUG: TEV-48574|DRUG: Placebo Details
NCT05471492 Study to Evaluate the Efficacy and Safety of PF-06480605 in Adult Participants With Moderate to Severe Crohn's Disease PHASE2 WITHDRAWN Telavant, Inc. Crohn Disease DRUG: Investigational Product|DRUG: Placebo Details
NCT05389709 A Pharmacy-based Observational Study to Learn More About Iberogast Advance in the Real-world Setting NULL COMPLETED Bayer Functional Gastrointestinal Disorders Such as Irr… DRUG: Iberogast (STW5-II, BAY98-7410) Details
NCT05377580 A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis PHASE2 COMPLETED Innovent Biologics (Suzhou) Co. Ltd. Ulcerative Colitis (UC) DRUG: Period 1 IBI112 Placebo|DRUG: Period 2 IBI1… Details
NCT05242484 A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis PHASE2 ACTIVE_NOT_RECRUITING Janssen Research & Development, LLC Colitis, Ulcerative BIOLOGICAL: Guselkumab|BIOLOGICAL: Golimumab|BIOL… Details
NCT05242471 A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease PHASE2 ACTIVE_NOT_RECRUITING Janssen Research & Development, LLC Crohn's Disease BIOLOGICAL: Guselkumab|BIOLOGICAL: Golimumab|BIOL… Details
NCT05177835 Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis PHASE2 ACTIVE_NOT_RECRUITING Abivax S.A. Ulcerative Colitis DRUG: ABX464 Details
NCT05118919 A Safety Study of Lactobacillus Reuteri BGP-014 in Patients With Ulcerative Colitis PHASE1|PHASE2 COMPLETED BioGaia Pharma AB Ulcerative Colitis BIOLOGICAL: BGP-014|BIOLOGICAL: Placebo Details
NCT05107492 Evaluation of the Pharmacokinetics, Safety and Tolerability of Single Dose of PF-06480605 in Chinese Healthy Participants PHASE1 COMPLETED Pfizer Inflammatory Bowel Disease DRUG: 450mg|DRUG: 150mg|DRUG: Placebo Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
S01 Anti-inflammatory inflammatory 5-Aminosalicylates (5-ASAs); corticosteroids Crohn's disease and ulcerative colitis are the two main com… Details
S06 Anti-fibrosis fibrosis; tissue remodelling GS-5745; STNM01 Tissue remodelling and destruction in patients with IBD is … Details
S07 Blockade of cytokine Cytokine signalling apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab Various T-cell subsets, their differentiation pathways and … Details

The case of a bloody mess - Bictegravir/emtricitabine/tenofovir alafenamide ind…

PMID: 40089176
Year: 2025
Relationship Type: Association Score: 6.5

BACKGROUND: Fecal calprotectin is a marker used to differentiate inflammatory bowel disease versus irritable bowel syndrome and is relevant in the di…

View Details